The AD-group included 17 variants (APOE (1), APOE (2), SCIMP, PLCG2 (1), MS4A6A, BIN1, PILRA, APP, PLCG2 (2), CR1, SLC24A4, TREML2, ACE, APH1B, FERMT2, PICALM, CD33) and the Longevity-group included 11 variants (SHARPIN (1), SHARPIN (2), HS3ST1, EPAH1, IQCK, PRKD3, CD2AP, PLCG2 (3), SPI1, HLA, ECHDC3), such that the effect of 28/38 (74%) of all variants was in the expected direction. This evidence concerns the gene APOE and Alzheimer disease.